ProdIgY Biotech
ApprovedWe are pioneering IgY-based antibody therapeutics to revolutionize the treatment of liver diseases through microbiome modulation. Our cutting-edge research and technology harness the unique properties of avian-derived antibodies to selectively neutralize harmful microbial components while preserving beneficial gut flora. By targeting the gut-liver axis, we aim to develop first-in-class, non-invasive therapies that address the root causes of alcohol-associated hepatitis (AH).
About
We are pioneering IgY-based antibody therapeutics to revolutionize the treatment of liver diseases through microbiome modulation. Our cutting-edge research and technology harness the unique properties of avian-derived antibodies to selectively neutralize harmful microbial components while preserving beneficial gut flora. By targeting the gut-liver axis, we aim to develop first-in-class, non-invasive therapies that address the root causes of alcohol-associated hepatitis (AH).
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile